Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1235)	7/2/2002 11:58:07 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 2243

heheh, and I want an apology from this guy too: Wednesday March 27, 8:55 am Eastern Time Morningstar.com Stock Analyst Notes: 03/27/02 By Morningstar Analysts Here's Morningstar's daily briefing on stocks we cover. (snip) Josh Peters Standard & Poor's followed the lead of Moody's on Tuesday by cutting the debt rating on Elan (NYSE: ELN - news). S&P dropped Elan's rating from BBB to BBB-, just one step from junk. Last week, Moody's lowered its rating for the second time in as many months to Ba2, which is junk status. It appears that both rating agencies are concerned that Elan may undertake an expensive acquisition that could increase its already high debt load and threaten cash flow. We agree that if Elan goes on a buying spree cash flows could suffer, but for now, its $2.2 billion in cash and equivalents and growing drug revenue ease our concerns. Elan is grossly undervalued, in our opinion. Elan traded at $9.86 that day. But me not so smart for buying it at $2.4 today I think. A couple percent of my net worth is going away fast. It makes my head spin. Thank goodness I didn't buy more.